p27 deficiency cooperates with Bcl-2 but not Bax to promote T-cell lymphoma

PLoS ONE

Volumn 3, Issue 4, 2008, Pages

  Cheng, Ningli ^a,b   van de Wetering, Christopher I ^a   Knudson, C Michael ^a  

^a UNIVERSITY OF IOWA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; PROTEIN BAX; PROTEIN BAX38; PROTEIN BCL 2; PROTEIN KINASE LCK; PROTEIN P27; CCND2 PROTEIN, MOUSE; CD3 ANTIGEN; CDK2 PROTEIN, MOUSE; CYCLINE; P27 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; HYPERPLASIA; LYMPHOBLASTOMA; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PENETRANCE; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; T CELL LYMPHOMA; T LYMPHOCYTE; THYMUS LYMPHOMA; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; THYMUS;

MUS; MUS MUSCULUS;

ANIMALS; ANTIGENS, CD3; BCL-2-ASSOCIATED X PROTEIN; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; CYCLINS; GENE EXPRESSION REGULATION, NEOPLASTIC; LYMPHOMA, T-CELL; MICE; MICE, TRANSGENIC; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES; THYMUS GLAND;

EID: 44849092993     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001911     Document Type: Article

References (57)

1. Cleary ML, Sklar J (1985) Nucleotide sequence of a t(14:18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-duster region new a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 82: 7439-7443.
2. Bakhshi A, Jersen JP, Goldman P, Wright JJ, McBride OW, et al. (1985) Cloning the chromosomal breakpoint of t(14; 18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41: 899-906.
3. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM (1985) The t(14:18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229: 1390-1393.
4. Chao DT, Korsmeyer SJ (1998) BCL-2 Family -Regulators of Cell Death. Annual Review of Immunology 16: 395-419.
5. Kuwana T, Newmeyer DD (2003) Bcl-2-family proteins and the role of mitochondria in apoptosis. Current Opinion in Cell Biology 15: 691-699.
6. Breckenridge DG, Xue D (2004) Regulation of mitochondrial membrane premeabilization by BCL-2 family proteins and caspases. Current Opinion in Cell Biology 16: 647-652.
7. Harris MH, Thompson CB (2000) The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death & Differentiation 7: 1182-1191.
8. MacCarthy-Morrogh L, Mouzakiti A, Townsend P, Brimmell M, Packham G (1999) Bcl-2-related proteins and cancer. Biochemical Society Transactions 27: 785-789.
9. Meterissian SH, Kontogiannea M, Al-Sowaidi M, Linjawi A, Halwani F, et al. (2001) Bcl-2 is a useful prognostic marker in Dukes' B colon caqcer. Annals of Surgical Oncology 8: 533-537.
10. Buglioni S, D'Agnano I, Cosimelli M, Vasselli S, D'Angelo C, et al. (1999) Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and Bcl-2. International Journal of Cancer 84: 545-552.
11. Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, et al. (1997) Prognostic significance of bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. International Journal of Cancer 74: 346-358.
12. Ofner D, Riehemann K, Maier H, Riedmann B, Nehoda H, et al. (1995) lmmunohistochemically detectable bcl-2 expression in colorectal carcinoma-correlation with tumour stage and patient survival. British Journal of Cancer 72: 981-985.
13. Kaklamanis L, Savage A, Whitehouse R, Doussis-Anagnostopoulou I, Biddolph S, tt al. (1998) Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer. British Journal of Cancer 77: 1864-1869.
14. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, et al. (1994) The bcl-2 protein-a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. Journal of the National Cancer Institute 86: 499-504.
15. de la Coste A, Mignon A. Fabre M, Gilbert F, Porten. A, et al. (1999) Paradoxical inhibition of c-myc-induced careinogenesis by Bcl-2 in transgenic mice. Cancer Research 59: 5017-5022.
16. Murphy KL, Kittrell FS, Gay JP, Jager R, Medina D, et al. (1999) Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracenetreated transgenic mice. Oncogene 18: 6597-6604.
17. Rossiter H, Beissert S, Mayer C, Schon MP, Wienrich BG, et al. (2001) Targeted expression (if bcl-2 to murine basal epidermal keratinocytes results in paradoxical retardation of ultraviolet- and chemical-induced tumorigenesis. Cancer Research 61: 3619-3626.
18. Luke JJ, Van de Wetering CI, Knudson CM (2003) Lymphoma development in Bax transgenc ruce is inhibited by Bcl-2 and associated with chromosomal instability. Cell Death & Differentiation 10: 740-748.
19. van de Wetering CI, Knudson CM (2007) Chromosomal instability and supernumerary centrosomes represent precursor defects in a mouse model of T-cell lymphoma. Cancer Res 67: 8081-9088.
20. Marvel J, Perkins GR, Lopez Rivas A, Collins MK (1994) Growth factor starvation of bcl-2 overexpressing murine bone marrow cells induced refractoriness to IL-3 stimulation of proliferation. Oncogene 9: 1117-1122.
21. Huang DC. O'Reilly LA, Strasser A, Cory S (i997) The anti-apoptosi function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO Journal 16: 462B-4638.
22. Vairo G, Innes KM, Adams JM (1996) Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 13: 1511-1519.
23. O'Reilly LA,Huang DC, Strasser A (1996) The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO Journal 15: 6979-6990.
24. O'Reilly LA, Harris AW, Tarlinton DM, Corcoran LM, Strasser A (1997) Expression of a Bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. Journal of Immunology 159: 2301-2311.
25. O'Reilly LA, Harris AW, Strasser A (1997) bcl-2 transgene expression promotes survival and reduce proliferation of CD3-CD4-CD8- T cell progenitors. International Immunology 9: 1291-1301.
26. Linette GP, Li Y, Roth KA, Korsmeyer SJ (1996) Crosstalk between cell death and cell cycle progression: Bcl-2 regulates NFAT-mediated activation. Proc Natl Acad Sci U S A 93: 9545-9552.
27. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, et al. (1991) Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A 88: 8661-8665.
28. Janumyan YM, Sansam CG, Chattopadhyay A, Cheng NL, Soucie EL, et al. (2003) Bcl-x(L)/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO Journal 22: 5459-5470.
29. Cheng NL, Janumyan YM, Didion L, Van Hofwegen P, Yang E, et al. (2004) Bcl-2 inhibition of T-cell proliferation is related to prolonged T-cell survival. Oncogene 23: 3770-3780.
30. Vairo G, Soos FJ, Upton TM, Zalvide J, DeCaprio JA, et al. (2000) Bcl-2 retards cell cycle entry through p27(Kipl), pRB relative p130; and altered E2F regulation. Molecular & Cellular Biology 20: 4745-4753.
31. Sherr GJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of Gl-phase progression. Genes & Development 13: 1501-1512.
32. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ (1991) Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67: 879-888.
33. Knudson CM, Korsmeyer SJ (1997) Bcl-2 and Bax function independently to regulate cell death. Nature Genetics 16: 358-363.
34. Greider C, Chattopadhyay A, Parkhurst C, Yang E. (2002) BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of Gl cyclin-dependent kinases. Oncogene 21: 7765-7775.
35. Holmes JK, Solomon MJ (2001) The role of thr160 phosphorylation of Cdk2 in substrate recognition, Eur J Biochem 268: 4647-4653.
36. Linette GP, Hess JL, Sentman CL, Korsmeyer SJ (1995) Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice. Blood 86: 1255-1260.
37. Nakayama K, Ishida N, Shirane M, inomata A, Inoue T, et al. (1996) Mice lacking p27 kipl) display increased body size, multiple organ hyperplsia retinal desplasia, and pituitary tumors. Cell 83: 707-720.
38. Knudson CM, Johnson GM, Lin Y, Korsmeyer SJ (2001) Bax accelerates tumorigenesis in p53-deficient mice. Cancer Research 61: 659-665.
39. Nakayama K, Nakayama K (1998) Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. Bioessays 20: 1020-1029.
40. Roussel NE (1999) The INK4 family of cell cycle inhibitors in cancer. Oncogene 18: 5311-5317.
41. Sharpless NE, Bardeesy N, Lee KA, Carrasco D, Castrillon DH, et al. (2001) Loss of p161nk4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413: 86-91.
42. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, et al. (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557: 592.
43. Deng CX, Zhang PM, Harper JW, Elledge SJ, Leder P (1995) Mice lacking p21(c/p1/waf1) undergo normal development, but are defective in g1 checkpoint control. Cell 82: 675-684: 698.
44. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, et al. (1996) Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85: 721-732.
45. Fero-ML, Randel E, Gurley KF, Robert JM, Kemp CJ (1998)The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177-180.
46. Martin-Caballero J, Flores JM, Garcia-Palencia P, Collado M, Serrano M (2004) Different cooperating effect of p21 or p27 deficiency in combination with INK4a/ARF deletion in mice. Oncogene 23: 8231-8237.
47. Cip1 during tumor development. Oncogene 23: 905-913.
48. Cip1 decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J 21: 3739-3748.
49. Kip1 cooperates with cyclin E in T-cell lymphomagenesis. Oncogene 22: 1724-11219.
50. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, et al. (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1: 289-298.
51. Gurova KV, Kwek SS, Koman IE, Komarov AP, Kandel E, et al. (2002) Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantars for p53-deficient cells in the tumor. Cancer Biology & Therapy 1: 39-44.
52. Callagy GM. Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, et al. (2006) Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index. Clin Cancer Res 12: 2468-2475.
53. Rathmell JC, Vander Heiden MG, Harris MH, Frauwirth KA, Thompson CB (2000) In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size viability. Molecular Cell 6: 683-692.
54. Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24.
55. Engedal N, Gjevik T, Blomhoff R. Blomhoff HK f2006) All-trans Retinoic Acid Stimulates IL-2-Mediated Proliferation of Human T Lymphocytes: Early Induction of Cyclin D3. J Immunol 177: 2851-2861.
56. Emerson DF, McCormick ML, Schmidt JA, Knudson, CM (20051 Taurine monochloramine activates a cell death pathway involving Bax and caspase-9. Journal of Biological Chemistry 280: 3233-3241.
57. Hadzic T, Li L, Cheng N, Walsh SA, Spitz DR, et al. (2005) The role of low molecular weight thiols in T lymphocyte proliferation and IL-2 secretion. J Immunol 175: 7965-7972.